A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
← catalyst calendarNCT07245992 · readout in 773 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
42estimated
Sites
2
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-04 | actual | When the study began enrolling |
| Primary completion | 2028-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis (RA)
Intervention
- Drug: F8IL10
Primary outcomes
what the primary-completion date above is the date OFDLT
measured From Day 1 to Day 28 of the treatment
MAD, MTD and RD
measured From Day 1 to Day 28 of the treatment
AEs, SAEs and DILI
measured Through study completation (up to 37 weeks)
Incidence of injection site reactions
measured Through study completation (up to 37 weeks)
Standard laboratory parameters
measured Through study completion (up to 37 weeks)
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed